Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wild-type RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: This disclosure provides an improved assay capable of identifying and distinguishing viral variants, such as SARS-CoV-2 variants and subvariants, including Alpha, Beta, Gamma, Delta, and Omicron, with high specificity and sensitivity. The disclosed assay can be used for real-time monitoring of viral variants (e.g., SARS-CoV-2 variants) spread without the need for whole-genome sequencing on all samples.

Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Abstract: The present invention is a method for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as a bacterium.

Abstract: The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes in Mycobacterium tuberculosis for identifying the presence of M.tb DNA and/or resistance to anti-tuberculosis drugs.

Abstract: The invention provides compounds of formula (I): and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Abstract: The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes in Mycobacterium tuberculosis for identifying the presence of M.tb DNA and/or resistance to anti-tuberculosis drugs.

Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wild-type RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: The invention provides compounds of formula (I): and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).

Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wild-type RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wild-type RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: The present invention relates to novel primers and sloppy molecular beacon and molecular beacon probes for amplifying segments from different genes in Mycobacterium tuberculosis for identifying the presence of M.tb DNA and/or resistance to anti-tuberculosis drugs.

Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wildtype RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes.

Abstract: This invention relates to nucleic acids, reagents and methods for detecting Rifampicin-resistant Mycobacterium tuberculosis in a sample from a subject. In one aspect, the invention provides methods of detecting Rifampicin resistant M. tuberculosis in a sample comprising (a) amplifying a nucleic acid containing the rifampicin resistance determining region (RRDR) of the rpoB gene in a sample to provide an amplified nucleic acid; (b) probing the amplified nucleic acid with at least three molecular beacon probes for an RRDR mutant target; (c) conducting melting temperature (Tm) analysis to determine a Tm value for each probe; and (d) comparing the Tm value for each probe with a Tm value for a wild-type RRDR region, wherein a Tm value for at least one of the molecular beacon probes that is greater than the Tm value for the wildtype RRDR indicates the presence of rifampicin resistant M. tuberculosis in the sample.

Abstract: A method for detecting and genotyping Escherichia coli O157:H7 strains, including detecting nucleotides at single nucleotide polymorphism (SNP) loci, the identity of which nucleotides define SNP genotypes. A method for genotyping E. coli O157:H7 strains, including detecting thirty-two nucleotides at thirty-two single nucleotide polymorphism (SNP) loci, the identity of which nucleotides define thirty-six SNP genotypes. Multiplexed primer trios capable of detecting the nucleotides at E. coli SNP loci, and a kit including one or more primer trios.

Abstract: The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes.

Abstract: The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterial gene) in a sample using a pool (e.g., 2, 3, 4, or more) of oligonucleotide hybridization probes.

Abstract: Method and kits for detecting a single nucleotide polymorphism in an organism via hairpin shaped primers that discriminate between different alleles by situating the 3? nucleotide at the location of a single nucleotide polymorphism are provided.

Abstract: This invention relates to the identification, cloning, sequencing and characterization of the iniB, iniA and iniC genes of mycobacteria which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid and ethambutol. The present invention provides purified and isolated iniB, iniA, iniC and iniB promoter nucleic acids which may comprise the iniBAC operon, as well as mutated forms of these nucleic acids. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the iniB, iniA, iniC and iniB promoter nucleic acids, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of drug-resistant mycobacterial strain. The present invention also provides methods for the screening and identification of drugs effective against Mycobacterium tuberculosis using induction of the iniB promoter.